Lung Cancer News
Week Ending June 28, 2021

Adagrasib for KRAS G12C+ Lung Cancer Granted Breakthrough Therapy Designation by FDA
“The FDA has granted a breakthrough therapy designation (BTD) from the FDA for patients with advanced non-small cell lung cancer (NSCLC) with a KRASG12C mutation following prior systemic treatment, according to a press release by Mirati Therapeutics, Inc.”

What Is a Liquid Biopsy for Lung Cancer — and Do You Need One?
“A liquid biopsy is a blood test designed to detect cancer cells, or DNA fragments from cancer cells, that circulate in the bloodstream. While a liquid biopsy may be useful for several different types of cancer, researchers are particularly excited about its potential for aiding in the diagnosis and treatment of lung cancer.”

Garassino Highlights What’s In Store for Lung Cancer
“Patients with lung cancer were identified as an at-risk group for developing severe complications as a result of SARS-CoV-2 infection, and thoracic oncologists were fast to respond with the establishment of the Thoracic Cancers International COVID-19 Collaboration.”

Radiation therapy for non-small cell lung cancer explained
“Treatment for non-small cell lung cancer (NSCLC) will depend on the stage of the condition. If the cancer is at an early stage, treatment such as radiation will aim to destroy the cancerous cells and cure the disease. If the cancer has progressed, radiation therapy may help prolong a person’s life.”

Lopes Shines a Light on the Explosion of Targeted Therapies in Lung Cancer Treatment Arsenal
“Now that several targeted agents have acquired regulatory approval across settings in the lung cancer paradigm, real-world considerations for the utilization of these agents in practice are warranted, and determining how they fit in and measure up with other available options in the arsenal is necessary to optimize their use, according to Gilberto Lopes, MD.”

Quest Diagnostics to Offer Biocept’s Target Selector NGS Lung Cancer Test
“NEW YORK — Biocept said on Tuesday that it has entered a collaboration with Quest Diagnostics to provide its Target Selector next generation-sequencing-based liquid biopsy lung cancer panel to Quest patients.”

Campaign aims to increase use of ‘crucial’ biomarker testing in NSCLC
“National Comprehensive Cancer Network guidelines recommend all patients with advanced nonsquamous non-small cell lung cancer undergo biomarker testing.”

Rural areas lack access to CT lung cancer screening
“June 25, 2021 — A hospital’s geographic location can influence what kinds of services it offers, and low-dose CT (LDCT) for lung cancer screening may not be available to many living in rural areas, according to a study published June 15 in the Annals of the American Thoracic Society.”

IMpower010: Post-Op Atezolizumab Improves DFS in Lung Cancer
“— Jack West opens the debate about whether DFS endpoint is sufficient to change practice”